These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 20629739)

  • 1. Cutaneous T-cell lymphoma cells are sensitive to rapamycin.
    Kremer M; Sliva K; Klemke CD; Schnierle BS
    Exp Dermatol; 2010 Sep; 19(9):800-5. PubMed ID: 20629739
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of IkappaB kinase subunit 2 in cutaneous T-cell lymphoma down-regulates nuclear factor-kappaB constitutive activation, induces cell death, and potentiates the apoptotic response to antineoplastic chemotherapeutic agents.
    Sors A; Jean-Louis F; Bégué E; Parmentier L; Dubertret L; Dreano M; Courtois G; Bachelez H; Michel L
    Clin Cancer Res; 2008 Feb; 14(3):901-11. PubMed ID: 18245554
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The rapamycin-sensitive signal transduction pathway as a target for cancer therapy.
    Hidalgo M; Rowinsky EK
    Oncogene; 2000 Dec; 19(56):6680-6. PubMed ID: 11426655
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mammalian target of rapamycin, a molecular target in squamous cell carcinomas of the head and neck.
    Amornphimoltham P; Patel V; Sodhi A; Nikitakis NG; Sauk JJ; Sausville EA; Molinolo AA; Gutkind JS
    Cancer Res; 2005 Nov; 65(21):9953-61. PubMed ID: 16267020
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Inhibition of cell growth by rapamycin through targeting mammalian target of rapamycin signaling pathway in nasopharyngeal carcinoma].
    Li YL; Zhang X; Liu Y; Li SS; Xie L; Zhang N; Liu XB; Tian YQ
    Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2010 Sep; 45(9):765-8. PubMed ID: 21092676
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mammalian target of rapamycin: discovery of rapamycin reveals a signaling pathway important for normal and cancer cell growth.
    Gibbons JJ; Abraham RT; Yu K
    Semin Oncol; 2009 Dec; 36 Suppl 3():S3-S17. PubMed ID: 19963098
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activity of pentostatin (Nipent) in cutaneous T-cell lymphoma: single-agent and combination studies.
    Foss FM
    Semin Oncol; 2000 Apr; 27(2 Suppl 5):58-63. PubMed ID: 10877054
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sirolimus inhibits human pancreatic carcinoma cell proliferation by a mechanism linked to the targeting of mTOR/HIF-1 alpha/VEGF signaling.
    Wang Y; Zhao Q; Ma S; Yang F; Gong Y; Ke C
    IUBMB Life; 2007 Nov; 59(11):717-21. PubMed ID: 17968710
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antiproliferative and proapoptotic effects of rapamycin and celecoxib in malignant melanoma cell lines.
    Bundscherer A; Hafner C; Maisch T; Becker B; Landthaler M; Vogt T
    Oncol Rep; 2008 Feb; 19(2):547-53. PubMed ID: 18202806
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cutaneous T cell lymphoma: the helping hand of dendritic cells.
    Edelson RL
    Ann N Y Acad Sci; 2001 Sep; 941():1-11. PubMed ID: 11594563
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A selective small molecule c-MET Inhibitor, PHA665752, cooperates with rapamycin.
    Ma PC; Schaefer E; Christensen JG; Salgia R
    Clin Cancer Res; 2005 Mar; 11(6):2312-9. PubMed ID: 15788682
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Response of U87 glioma xenografts treated with concurrent rapamycin and fractionated radiotherapy: possible role for thrombosis.
    Weppler SA; Krause M; Zyromska A; Lambin P; Baumann M; Wouters BG
    Radiother Oncol; 2007 Jan; 82(1):96-104. PubMed ID: 17161482
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rapamycin inhibits proliferation of estrogen-receptor-positive breast cancer cells.
    Chang SB; Miron P; Miron A; Iglehart JD
    J Surg Res; 2007 Mar; 138(1):37-44. PubMed ID: 17109887
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacodynamic Evaluation of CCI-779, an Inhibitor of mTOR, in Cancer Patients.
    Peralba JM; DeGraffenried L; Friedrichs W; Fulcher L; Grünwald V; Weiss G; Hidalgo M
    Clin Cancer Res; 2003 Aug; 9(8):2887-92. PubMed ID: 12912932
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cell signaling. New mTOR targets Grb attention.
    Yea SS; Fruman DA
    Science; 2011 Jun; 332(6035):1270-1. PubMed ID: 21659593
    [No Abstract]   [Full Text] [Related]  

  • 16. [Cutaneous lymphoma of the Sézary and Bouvrain type. Progress in physiopathologic and therapeutic outlook].
    Bagot M
    Bull Acad Natl Med; 1998; 182(5):927-37; discussion 937-8. PubMed ID: 9735499
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An expanding role for mTOR in cancer.
    Guertin DA; Sabatini DM
    Trends Mol Med; 2005 Aug; 11(8):353-61. PubMed ID: 16002336
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Constitutive activation of signal transducers and activators of transcription predicts vorinostat resistance in cutaneous T-cell lymphoma.
    Fantin VR; Loboda A; Paweletz CP; Hendrickson RC; Pierce JW; Roth JA; Li L; Gooden F; Korenchuk S; Hou XS; Harrington EA; Randolph S; Reilly JF; Ware CM; Kadin ME; Frankel SR; Richon VM
    Cancer Res; 2008 May; 68(10):3785-94. PubMed ID: 18483262
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Calorie restriction and rapamycin inhibit MMTV-Wnt-1 mammary tumor growth in a mouse model of postmenopausal obesity.
    Nogueira LM; Dunlap SM; Ford NA; Hursting SD
    Endocr Relat Cancer; 2012 Feb; 19(1):57-68. PubMed ID: 22143497
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vivo imaging of cutaneous T-cell lymphoma migration to the skin.
    Hoeller C; Richardson SK; Ng LG; Valero T; Wysocka M; Rook AH; Weninger W
    Cancer Res; 2009 Apr; 69(7):2704-8. PubMed ID: 19318575
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.